For patients with obesity, the choice between Mounjaro (tirzepatide) and Wegovy (semaglutide 2.4 mg) is a central question in 2026. Both treatments are specifically approved for weight management, but their clinical results, mechanisms, and safety profiles present important differences that patients and doctors should be aware of.
Indications and Approvals
It is essential to distinguish the indications for each molecule:
- Mounjaro (tirzepatide): initially approved for type 2 diabetes. Its equivalent for obesity is Zepbound (same molecule, same dosage, obesity indication). In France, the name Mounjaro is used for both indications.
- Wegovy (semaglutide 2.4 mg): specifically approved for weight management in adults with a BMI ≥30 kg/m2 or ≥27 kg/m2 with comorbidities. This is the “high-dose” version of semaglutide, with Ozempic being limited to 2 mg for diabetes.
Both treatments are approved by the EMA (European Medicines Agency) and the FDA, but reimbursement conditions in France differ.
Weight Loss: Comparative Figures
Efficacy in weight loss is the most important comparison criterion for obese patients:
| Result | Mounjaro/Zepbound 15 mg | Wegovy 2.4 mg | Difference |
|---|---|---|---|
| Average weight loss | -22.5 % | -16.9 % | +5.6 points |
| Weight loss in kg (100 kg patient) | -22.5 kg | -16.9 kg | +5.6 kg |
| Patients ≥5 % loss | 96 % | 87 % | +9 points |
| Patients ≥10 % loss | 89 % | 69 % | +20 points |
| Patients ≥20 % loss | 57 % | 32 % | +25 points |
| Patients ≥25 % loss | 36 % | 12 % | +24 points |
Source: SURMOUNT-1 (tirzepatide, Jastreboff et al., NEJM 2022) and STEP-1 (semaglutide, Wilding et al., NEJM 2021).
The difference is particularly striking for significant weight loss: 3 times more patients achieve -20% with Mounjaro than with Wegovy. This difference is explained by the synergistic action on both GIP and GLP-1 receptors.
Body Composition: Fat vs Muscle
A major challenge in pharmacological weight loss is the preservation of muscle mass. GLP-1 agonists are regularly criticized for their impact on lean mass.
Data from SURMOUNT-1 show that with tirzepatide 15 mg:
- 85.1% of total weight loss comes from fat mass
- 14.9% comes from lean mass (mainly water and muscle glycogen)
- The fat/lean mass ratio is more favorable than with diet alone (generally 60-70% fat)
With semaglutide 2.4 mg, available data (STEP-1, DEXA analyses) show a comparable but slightly less favorable ratio, with approximately 75-80% of the loss coming from fat mass. The action of GIP on adipose tissue could explain this advantage of tirzepatide.
Compared Side Effects
Tolerance profiles are generally similar, with a predominance of gastrointestinal symptoms:
| Side Effect | Mounjaro 15 mg | Wegovy 2.4 mg |
|---|---|---|
| Nausea | 24 % | 44 % |
| Diarrhea | 17 % | 30 % |
| Vomiting | 9 % | 24 % |
| Constipation | 11 % | 24 % |
| Fatigue | 5 % | 11 % |
| Discontinuation due to AE | 6.5 % | 7.0 % |
A notable point: nausea and vomiting are significantly less frequent with Mounjaro. The signaling bias of tirzepatide on the GLP-1R (favoring cAMP over beta-arrestin) reduces emetogenic effects while maintaining metabolic efficacy.
Cardiovascular Benefits
Wegovy has a major advantage: the SELECT study (17,604 patients, published in NEJM in 2023) demonstrated a 20% reduction in major adverse cardiovascular events (MACE: myocardial infarction, stroke, cardiovascular death) in obese non-diabetic patients. This is the first obesity treatment to prove a cardiovascular benefit.
Mounjaro/Zepbound: the SURPASS-CVOT study (tirzepatide vs placebo in diabetic patients with cardiovascular risk) is still ongoing. Indirect data are promising: improvement in triglycerides (-25%), HDL-cholesterol, blood pressure, and CRP. However, without the results of a dedicated cardiovascular trial, Mounjaro cannot claim a proven cardiovascular benefit.
Compared Practical Modalities
| Criterion | Mounjaro | Wegovy |
|---|---|---|
| Frequency | 1x/week | 1x/week |
| Administration route | Subcutaneous | Subcutaneous |
| Pen type | Pre-filled pen | Pre-filled pen |
| Visible needle | No (hidden needle) | No (hidden needle) |
| Initial dose | 2.5 mg | 0.25 mg |
| Maximum dose | 15 mg | 2.4 mg |
| Titration steps | 6 steps (4 weeks) | 5 steps (4 weeks) |
| Time to max dose | 20 weeks | 16 weeks |
| Storage | Refrigerator / 21 days at room temp | Refrigerator / 28 days at room temp |
Which Treatment to Choose?
The decision must be made jointly with the prescribing physician based on the individual profile:
Prioritize Mounjaro/Zepbound if:
- Maximum desired weight loss (>20%)
- Associated type 2 diabetes requiring strict glycemic control
- Previous digestive intolerance to a pure GLP-1 agonist
- Associated hepatic steatosis (NASH)
- Body composition: preservation of lean mass is a priority
Prioritize Wegovy if:
- Cardiovascular history (proven SELECT benefit)
- Patient at high cardiovascular risk without diabetes
- Established medical experience with the molecule (older)
- Cost and reimbursement considerations
Key Takeaways
In 2026, Mounjaro/Zepbound is the most effective treatment available for weight loss, with an advantage of 5 to 6 percentage points over Wegovy. However, Wegovy has unique cardiovascular data (SELECT study) that make it the preferred choice for patients at cardiovascular risk. Both treatments are major therapeutic advances that have transformed obesity management.
FAQ
Does Mounjaro cause more weight loss than Wegovy?
Yes. Studies show a weight loss of 22.5% with Mounjaro 15 mg versus 16.9% with Wegovy 2.4 mg. The difference is particularly marked for significant losses: 57% of patients lose more than 20% with Mounjaro compared to 32% with Wegovy.
Is Wegovy safer for the heart?
Wegovy is the only one to have proven a cardiovascular benefit in a dedicated trial (SELECT study: -20% MACE events). The equivalent study for Mounjaro is ongoing. Both molecules improve cardiovascular risk factors.
Are nausea worse with one or the other?
Wegovy causes more nausea (44%) than Mounjaro (24%). This difference is linked to the mechanism of action: tirzepatide has a signaling bias on the GLP-1 receptor that reduces emetogenic effects.
Can one switch from Wegovy to Mounjaro?
Yes, with medical supervision. The transition is made by restarting tirzepatide at 2.5 mg. The doctor adapts the protocol according to the patient’s tolerance and response.
Are Zepbound and Mounjaro the same thing?
Yes. Zepbound is the commercial name for tirzepatide for the obesity indication in the United States. Mounjaro is the name for the type 2 diabetes indication. In France, the name Mounjaro is used for both indications. Same molecule, same doses.
Sources
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM. 2022;387:205-216. (SURMOUNT-1)
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM. 2021;384:989-1002. (STEP-1)
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM. 2023;389:2221-2232. (SELECT)
- Frias JP et al. SURPASS-2. NEJM. 2021;385:503-515.
- EMA. EPAR Mounjaro, 2022. EPAR Wegovy, 2022.